Home > Healthcare > Drug Device Combination > Therapeutic Systems > Guillain-Barre Syndrome (GBS) Market

Guillain-Barre Syndrome (GBS) Market Share

Report ID: GMI9361
Published Date: May 2024
Report Format: PDF

Download Free Sample

Guillain-Barre Syndrome Market Share

The key players within the competitive landscape prioritize vying for product effectiveness, safety credentials, pricing tactics, and geographical reach. Primary areas of concentration involve R&D, strategic partnerships, and initiatives for market expansion. These endeavours aimed to secure a competitive advantage and bolster market share.

Guillain-Barre Syndrome Market Companies

Some of the prominent market players operating in the GBS industry include:

AbbVie Inc.
Biogen Inc.
Cadila Healthcare Limited
CSL Behring LLC
F. Hoffmann-La Roche Ltd.
GSK plc
Grifols SA
LGM Pharmaceuticals Inc.
Merck & Co. Inc.
Octapharma AG
Pfizer Inc.
Takeda Pharmaceutical Company Limited

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Guillain-Barre syndrome industry size recorded USD 645.2 million in 2023 and will exhibit a 4.6% CAGR between 2024 and 2032 due to the increasing prevalence of autoimmune diseases, growing healthcare infrastructure, and rising healthcare expenditure.

The first-line treatment segment in the Guillain-Barre syndrome industry will register 4.8% CAGR till 2032, driven by the crucial role of initial therapies, such as intravenous immunoglobulin and plasma exchange, in managing the condition effectively.

North America Guillain-Barre syndrome industry size was USD 305.4 million in 2023, owing to advanced healthcare infrastructure, heightened awareness, and extensive R&D activities in the region.

Key Guillain-Barre syndrome industry players are AbbVie Inc., Biogen Inc., Cadila Healthcare Limited., CSL Behring LLC, F. Hoffmann-La Roche Ltd., GSK plc, Grifols SA, LGM Pharmaceuticals Inc., Merck & Co. Inc., Pfizer Inc., and Takeda Pharmaceutical Company Limited., among others.